MARSHALL WACE, LLP

Position in TRVI — Trevi Therapeutics, Inc.

CIK 1318757 LONDON, X0

Position in TRVI

as of Mar 31, 2026 · filed May 15, 2026 Compact

Position Value

$47,314,606

-$10,033,853 QoQ

Shares Held

3,966,019

-13.4% QoQ

Ownership

2.79%

of shares outstanding

% of Portfolio

0.07%

of 13F equity value

Holder Rank

—

not a current holder

Holding Since

Mar 2022

9 quarters on record

Voting authority Sole 0.ToString("F0")% Shared 100.ToString("F0")% None 0.ToString("F0")%

Healthcare · as of Mar 31, 2026

MARSHALL WACE, LLP holds $2,749,797,393 across 275 Biotechnology names. TRVI ranks #14 (1.7% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	ALNY	Alnylam Pharmaceuticals, Inc.	1,099,318	$363,731,344
2	VRTX	Vertex Pharmaceuticals Inc / Ma	317,058	$141,579,078
3	INCY	Incyte Corp	1,253,138	$117,945,347
4	RPRX	Royalty Pharma plc	2,120,692	$101,729,594
5	RCUS	Arcus Biosciences, Inc.	3,761,437	$81,247,039
6	PTGX	Protagonist Therapeutics, Inc	628,075	$66,199,104
7	ROIV	Roivant Sciences Ltd.	2,246,943	$62,240,320
8	COGT	Cogent Biosciences, Inc.	1,600,168	$61,590,466

9 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-03-31	$47,314,606	3,966,019	-13.4%	Shares	Other	2026-05-15
2025-12-31	$57,348,459	4,580,548	-5.4%	Shares	Other	2026-02-13
2025-09-30	$44,302,021	4,841,751	+95.4%	Shares	Other	2025-11-13
2025-06-30	$13,554,200	2,477,916	-3.0%	Shares	Other	2025-08-13
2025-03-31	$16,066,049	2,554,221	+5851.0%	Shares	Other	2025-05-15
2024-12-31	$176,834	42,921	-47.1%	Shares	Other	2025-02-13
2024-09-30	$270,954	81,124	-36.8%	Shares	Other	2024-11-14
2022-09-30	$197,618	128,324	+448.3%	Shares	Other	2022-11-14
2022-03-31	$51,484	23,402	—	Shares	Other	2022-05-16
No filing history on record for this holder in this stock.